Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)

Inhibikase Therapeutics (IKT) has reported Current Deferred Revenue for 3 consecutive years, with $23683.0 the latest figure, recorded in Q3 2022.

• In Q3 2022, Current Deferred Revenue changed N/A year-over-year to $23683.0; the TTM figure through Sep 2022 stood at $23683.0 (changed N/A YoY), while the FY2020 annual figure was $2.3 million, changed N/A from the prior year.
• Current Deferred Revenue held at $23683.0 in Q3 2022 per IKT's latest filing, from $23684.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $2.3 million in Q4 2020 and bottomed at $23683.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $753415.2 across 3 years, with a median of $142619.0 in 2021.
• On a YoY basis, Current Deferred Revenue climbed as much as 83.39% in 2022 and fell as far as 83.39% in 2022.
• Inhibikase Therapeutics' Current Deferred Revenue stood at $2.3 million in 2020, then slumped by 93.87% to $142619.0 in 2021, then tumbled by 83.39% to $23683.0 in 2022.
• Business Quant data shows IKT's Current Deferred Revenue at $23683.0 in Q3 2022, $23684.0 in Q2 2022, and $142619.0 in Q2 2021.